News

Video

AAO 2024: Clinical trials of travoprost

Key Takeaways

  • Travoprost's intracamral delivery in iDose trials effectively lowers IOP in patients with prior failed SLT, offering a promising treatment alternative.
  • Direct delivery to the trabecular meshwork reduces ocular surface side effects, enhancing patient comfort and treatment adherence.
SHOW MORE

At this year's American Academy of Ophthalmology (AAO) meeting, John Berdahl, MD, spoke about the recent clinical trials of travoprost and its use in patients with prior SLT.

At this year's American Academy of Ophthalmology (AAO) meeting, John Berdahl, MD, spoke about the recent clinical trials of travoprost and its use in patients with prior SLT.

Editor's note: This transcript has been lightly edited for clarity.

John Berdahl, MD: Hello, John Berdahl here at the American Academy of Ophthalmology. I'm a ophthalmologist at Vance Thompson Vision in Sioux Falls, South Dakota, and was lucky to participate in the iDose clinical trials. And some of the data that we're presenting here is, how did iDose do in patients that had prior SLT, in particular those that had failed prior SLT. And the good news is it works. And you know, we know that prostaglandins work. We also know they can be tough on the surface of the eye. And so what we hope for is that by putting the travoprost directly inside the eye, we get better access to the trabecular meshwork with lower doses, and don't have to fight the barrier of the cornea or the side effects that come from applying a drug to the ocular surface. And indeed, that was the case.

And there's actually other data out there that shows that, in those big trials, the intracamral delivery of prostaglandins show that it lowers IOP even further. So it's good news for us. It's good news, most importantly, for our patients that in these difficult to treat patients, like those that had had a prior SLT, or maybe even in those that prostaglandins aren't quite good enough, that the iDose can help us in those situations.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.